References
- Graninger W, Sadighian R. History and future of pneumonia. Int J Clin Pract Suppl 2000;115:4–13
- Mandell LA, Bartlett JG, Dowell SF, File Jr TM, Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003;37:1405–33
- Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001;163:1730–54
- Ramirez J, Ahkee S. Cost analysis switching to oral antibiotics: A cost-savings strategy in the hospitalized patient. Drug Benefit Trends 1996;8: 20–2,28,34
- Ramirez JA, Srinath L, Ahkee S, Huang A, Raff MJ. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995;155:1273–6
- Ramirez JA, Vargas S, Ritter GW, Brier ME, Wright A, Smith S, et al. Early switch from intravenous to oral antibiotics and early hospital discharge. A prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med 1999;159:2449–54
- Sevinc F, Prins JM, Koopmans RP, Langendijk PNJ, Bossuyt PMM, Dankert J, et al. Early switch from intravenous to oral antibiotics: guidelines and implementation in a large teaching hospital. J Antimicrob Chemother 1999;43:601–6
- Clark LC, Davis CW. Experiences at a large teaching hospital with levofloxacin for the treatment of community-acquired pneumonia. Am J Health Syst Pharm 2000;57:S10–S13
- Kuti JL, Le TN, Nightingale CH, Nicolau DP, Quintiliani R. Pharmacoeconomics of a pharmacist-managed program for automatically converting levofloxacin route from i.v. to oral. Am J Health Syst Pharm 2002;59:2209–15
- Gunderson BW, Ross GH, Ibrahim KH, Rotschafer JC. What do we really know about antibiotic pharmacodynamics? Pharmaco-therapy 2001;21:302S–18S
- Lister PD. Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2002;44:43–9
- Jumbe N, Louie A, Leary R, Liu W, Deziel MR, Tam VH, et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 2003;112:275–85
- Guay DRP. Short-course antimicrobial therapy of respiratory tract infections. Drugs 2003;63:2169–84
- Dunbar LM, Wunderink RG, Habib MP, Smith LG, Tennenberg AM, Khashab MM, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003;37:752–60
- Mandell LA, File Jr TM. Short-course treatment of community-acquired pneumonia. Clin Infect Dis 2003;37:761–3
- Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243–50
- Feuer EJ, Kessler LG. Test statistic and sample size for a two-sample McNemar test. Biometrics 1989;45:629–36
- Altman DG. Practical Statistics for Medical Research. Chapman and Hall, 1991
- Miller RGJ. Survival Analysis. New York: John Wiley and Sons, 1981
- Thomson PDR. 2003 Drug Topics® Red Book. Montvale, NJ, 2003
- Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. JAMA 2000;283:749–55
- Feagan BG. A controlled trial of a critical pathway for treating community-acquired pneumonia: the CAPITAL study. Pharmacotherapy 2001;21:89S–94S
- Merchant S, Mullins CD, Shih YC. Factors associated with hospitalization costs for patients with community-acquired pneumonia. Clin Ther 2003;25:593–610
- Ramirez JA. Switch therapy in community-acquired pneumonia. Diagn Microbiol Infect Dis 1995;22:219–23